

"Express Mail" mailing label number EL018701613US

Date of Deposit April 12, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Queen Thomas  
Printed Name

*Queen Thomas*  
Signature

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Suad Efendic )  
 )  
For : USE OF GLP-1 OR ANALOGS IN )  
TREATMENT OF MYOCARDIAL )  
INFARCTION )  
 )  
Docket No. : X-10822A )

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE**  
**WITH 37 C.F.R. 1.821(f) (SEQUENCE LISTING)**

Assistant Commissioner for Patents

Washington, D. C. 20231

Sir:

I hereby affirm that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

*Mark J. Stewart*  
Mark J. Stewart, Ph.D.  
Attorney for Applicant  
Registration No. 43,936  
Phone: 317-276-0280

Eli Lilly and Company  
Patent Division/MJS  
Lilly Corporate Center  
Indianapolis, Indiana 46285

Apr 12, 2001

## SEQUENCE LISTING

<110> Efendic, Suad  
 <120> USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION  
 <130> X-10822A  
 <150> US 60/024,980  
 <151> 1996-08-30  
 <150> US 08/915,918  
 <151> 1997-08-21  
 <160> 6  
 <170> PatentIn version 3.0  
 <210> 1  
 <211> 31  
 <212> PRT  
 <213> Homo sapiens  
 <400> 1  
 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
 1 5 10 15  
 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly  
 20 25 30  
 <210> 2  
 <211> 31  
 <212> PRT  
 <213> Artificial  
 <220>  
 <223> synthetic construct  
 <220>  
 <221> VARIANT  
 <222> (1)..(1)  
 <223> Xaa at position 1 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, B-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and alpha-methyl-histidine  
 <220>  
 <221> VARIANT  
 <222> (2)..(2)  
 <223> Xaa at position 2 is Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala  
 <220>  
 <221> VARIANT  
 <222> (15)..(15)  
 <223> Xaa at position 15 is Glu, Gln, Ala, Thr, Ser, and Gly

<220>  
 <221> VARIANT  
 <222> (21)..(21)  
 <223> Xaa at position 21 is Glu, Gln, Ala, Thr, Ser, and Gly

<220>  
 <221> VARIANT  
 <222> (31)..(31)  
 <223> Xaa at position 31 is NH2 and Gly-OH

<400> 2

Xaa Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Xaa Gly  
 1 5 10 15

Gln Ala Ala Lys Xaa Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa  
 20 25 30

<210> 3  
 <211> 28  
 <212> PRT  
 <213> Artificial

<220>  
 <223> synthetic construct

<220>  
 <221> VARIANT  
 <222> (28)..(28)  
 <223> Xaa at position 28 is Lys and Lys-Gly

<400> 3

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
 1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Xaa  
 20 25

<210> 4  
 <211> 30  
 <212> PRT  
 <213> Artificial

<220>  
 <223> synthetic construct

<220>  
 <221> VARIANT  
 <222> (19)..(19)  
 <223> Xaa at position 19 is Lys or Arg

<220>  
 <221> VARIANT

<222> (30)..(30)

<223> Xaa at position 30 is Gly-OH or NH2

<400> 4

Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly Gln  
1 5 10 15

Ala Ala Xaa Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Xaa  
20 25 30

<210> 5

<211> 30

<212> PRT

<213> Artificial

<220>

<223> synthetic construct

<400> 5

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly  
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg  
20 25 30

<210> 6

<211> 4

<212> PRT

<213> Artificial

<220>

<223> synthetic construct

<400> 6

Ser Arg Arg Gln  
1